OncoMed Pharma (OMED) Tops Q4 EPS by 8c

OncoMed Pharma (NASDAQ: OMED) reported Q4 EPS of ($0.60), $0.08 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $8.89 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Marpai, Inc. (MRAI) Misses Q2 EPS by 18c
• Calamp Corp. (CAMP) Misses Q2 EPS by 33c